2 Jun by Vitaliy Dadalyan Tags:

Is Chewy, Inc. (CHWY) A Good Stock To Buy?

In this article we will check out the progression of hedge fund sentiment towards Chewy, Inc. (NYSE:CHWY) and determine whether it is a good investment right now. We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 […]...
2 Jun by Vitaliy Dadalyan Tags:

3 “Strong Buy” Penny Stocks That Could Go Boom

Penny stocks are controversial, to say the least. When it comes to these under $5 per share investment opportunities, Wall Street observers usually either love them or hate them. The penny stock-averse point out that while the bargain price tag is tempting, there could be a reason shares are trading at such low levels like poor fundamentals or insurmountable headwinds.However, the other side of the coin has merit as well. Naturally, with these cheap tickers, you get more bang for your buck in terms of the amount of shares. On top of this, other more expensive and well-known names aren’t as likely to produce the colossal gains that penny stocks are capable of.Given the nature of these investments, Wall Street analysts recommend doing some due diligence before pulling the trigger, noting that not all penny stocks are bound for greatness.With this in mind, we set out our own search for compelling...
2 Jun by Vitaliy Dadalyan Tags:

Exclusive: U.S. small business program handed out virus aid to many borrowers twice

A technical snafu in a U.S. government system caused many small businesses to receive loans twice or more under a federal aid program to help businesses hurt by the COVID-19 pandemic, nearly a dozen people with knowledge of the matter said. The money mistakenly handed out could amount to hundreds of millions of dollars that the government and lenders - which made the loans - have been trying to identify and recover in recent weeks, one of the people briefed on the matter said. The technical issue and scale of the resulting duplicate deposits made under the Small Business Administration's $660 billion Paycheck Protection Program (PPP) have not been previously reported....
2 Jun by Vitaliy Dadalyan Tags:

Bristol Myers Reveals Positive Results For Ulcerative Colitis Pivotal Trial

Bristol Myers Squibb (BMY) has announced positive results from True North, a pivotal Phase 3 trial evaluating oral Zeposia (ozanimod) as an induction and maintenance therapy for adult patients with moderate to severe ulcerative colitis.True North met both primary endpoints, demonstrating highly statistically significant (p-value < 0.0001) results for induction of clinical remission at Week 10 and in maintenance at Week 52.The study also met key secondary endpoints of clinical response and endoscopic improvement in induction at Week 10 and in maintenance at Week 52, BMY reported.At the same time, the safety profile of Zeposia in the True North trial was consistent with previously reported trials.BMY will now complete a full evaluation of the True North data and work with investigators to present detailed results at a future medical meeting, as well as discuss these results with health authorities.“Patients with ulcerative colitis can struggle to effectively manage this often unpredictable and potentially...